Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
暂无分享,去创建一个
B. Escudier | Y. Loriot | K. Fizazi | L. Albiges | L. Derosa | A. Guida | G. Baciarello | E. Colomba | F. Ruatta
[1] S. Culine,et al. Denosumab Toxicity When Combined With Anti‐angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study , 2019, Clinical genitourinary cancer.
[2] S. Baleato-González,et al. Specific criteria for tumor response. , 2018, Radiologia.
[3] R. Motzer,et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. , 2017, European urology.
[4] K. Ahrar,et al. Cryoablation of Bone Metastases from Renal Cell Carcinoma for Local Tumor Control , 2017, The Journal of bone and joint surgery. American volume.
[5] T. Powles,et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[6] S. Barni,et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? , 2015, Journal of experimental & clinical cancer research : CR.
[7] M. Staehler,et al. Local treatments for metastases of renal cell carcinoma: a systematic review. , 2014, The Lancet. Oncology.
[8] T. Choueiri,et al. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. , 2014, European urology.
[9] V. Torri,et al. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. , 2014, Future oncology.
[10] T. Choueiri,et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. , 2014, European urology.
[11] R. Montironi,et al. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside , 2014, Cancer and Metastasis Reviews.
[12] P. Tamboli,et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. , 2014 .
[13] S. Barni,et al. Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey , 2013, PloS one.
[14] R. Motzer,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[15] P. Brown,et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. , 2012, The Lancet. Oncology.
[16] Jonathan G Goldin,et al. Computer-aided quantitative bone scan assessment of prostate cancer treatment response , 2012, Nuclear medicine communications.
[17] T. Choueiri,et al. Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy , 2011, Cancer.
[18] J. Zucman‐Rossi,et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] A. Baur-Melnyk,et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment , 2010, BMC musculoskeletal disorders.
[20] M. Caraglia,et al. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). , 2007, Journal of experimental & clinical cancer research : CR.
[21] C. Cannon,et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. , 2007, The Journal of bone and joint surgery. American volume.
[22] B. Fuchs,et al. Solitary Bony Metastasis from Renal Cell Carcinoma: Significance of Surgical Treatment , 2005, Clinical orthopaedics and related research.
[23] J. Harrelson,et al. Treatment of Osseous Metastases in Patients With Renal Cell Carcinoma , 2003, Clinical orthopaedics and related research.
[24] H. Helenius,et al. Feasibility of prolonged use of interferon‐α in metastatic kidney carcinoma , 2001 .
[25] R. Coleman,et al. The skeletal metastatic complications of renal cell carcinoma. , 2001, International journal of oncology.
[26] R. Coleman. Should bisphosphonates be the treatment of choice for metastatic bone disease? , 2001, Seminars in oncology.
[27] R. Newcombe,et al. Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.
[28] R. Coleman. Monitoring of bone metastases. , 1998, European journal of cancer.
[29] G. Forbes,et al. Radiographic manifestations of bone metastases from renal carcinoma. , 1977, AJR. American journal of roentgenology.
[30] W. Gregory,et al. Skeletal complications and survival in renal cancer patients with bone metastases. , 2011, Bone.
[31] N. Kinnane. Burden of bone disease. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.